Semax: ACTH(4-10) analog, neurotrophic induction, and the neuroplasticity literature

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the 4-10 fragment of adrenocorticotropic hormone (ACTH) extended with a C- terminal Pro-Gly-Pro tripeptide that confers resistance to enzymatic degradation. Critically, the ACTH(4-10) core retains the neurotropic and behavioral effects of the parent hormone while being devoid of corticotropic activity — that is, Semax does not stimulate adrenal cortisol release [1, 7].

Semax was developed by the laboratory of Academician I.P. Ashmarin at Moscow State University in the 1980s and subsequently characterized in detail at the Institute of Molecular Genetics of the Russian Academy of Sciences. It was approved for clinical use in Russia in 2011 for stroke and cerebrovascular insufficiency [4]. As with Selank, this approval does not affect its research-use-only status elsewhere, but it produces a human clinical literature that is unusually deep for a compound in its class.

The most frequently cited mechanism for Semax is rapid induction of neurotrophic factors. Shadrina and colleagues (2001) demonstrated that Semax produced rapid increases in mRNA encoding BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in rat glial cell cultures within 20-40 minutes of exposure [2]. Dolotov et al. (2006) subsequently showed that Semax binds specifically in the rat basal forebrain and produces sustained increases in BDNF protein at the tissue level [5].

This neurotrophic footprint is central to the compound’s therapeutic rationale in models of cerebral ischemia. BDNF and NGF are principal mediators of neuronal survival, synaptic plasticity, and post-injury recovery; a compound that rapidly and reliably upregulates both is of obvious interest in stroke-recovery and cognitive-decline models.

A second axis is modulation of the melanocortin system. Although Semax lacks corticotropic activity, it retains some affinity for central melanocortin receptors, which mediate behavioral and attentional effects attributed to ACTH-derived peptides. This is invoked to explain the attentional and motivational effects described in early Ashmarin-group behavioral studies [1, 7].

A third, increasingly discussed axis is modulation of gene expression in vascular and immune pathways in the ischemic penumbra. Medvedeva et al. (2014) described broad transcriptional changes in rat brain tissue after focal ischemia, with Semax administration preferentially modulating genes involved in vascular tone and neutrophil- mediated inflammation [3]. This provides a second, non- neurotrophic pathway through which the compound may contribute to tissue protection in stroke models.

Modulation of monoaminergic tone has been reported in behavioral models of depression-like states and cholecystokinin-induced anxiety, with effects on serotonin and dopamine turnover in limbic structures [6].

Neuroprotection in stroke. Semax is most extensively characterized in rodent models of focal cerebral ischemia. Reports describe reduced infarct volume, improved neurological scores, and transcriptional signatures consistent with attenuated inflammatory response [3]. Gusev et al. (2005) published clinical data in patients with chronic cerebrovascular insufficiency describing reduced rate of disease progression [4].

Cognitive endpoints. The Ashmarin group published extensively on attentional and memory endpoints in both rodents and humans. Effects are most pronounced under conditions of fatigue, hypoxia, or sleep deprivation — the compound’s original operational application was aviation medicine, where it was studied as a protective agent against stress-induced cognitive degradation [1, 7].

Mood and affect. Levitskaya and colleagues described effects on emotional state in rats under both baseline and cholecystokinin-induced depression-like conditions, with Semax producing normalization of exploratory behavior [6]. The mechanism is proposed to involve combined monoaminergic and neurotrophic effects.

Safety and tolerability. The Russian clinical literature describes a benign safety profile across acute and extended use, with the principal caveat that long-term pharmacovigilance data at Western scale does not exist.

Semax, like Selank, was designed and studied principally for intranasal administration. The Russian clinical protocols use nasal drops at concentrations of 0.1% or 1.0% depending on indication, with dosing frequencies typically ranging from twice daily to four times daily in more acute protocols [4].

The intranasal route is thought to provide direct CNS access through the olfactory and trigeminal pathways, as described in the general nasal-peptide delivery literature. For a compound whose primary site of action is central — BDNF/NGF induction in basal forebrain and cortex — this delivery route is mechanistically aligned.

Research-grade Semax synthesized under HPLC verification is catalog-listed at /products/semax-nasal-spray.

Semax is commonly paired in research protocols with peptides operating through orthogonal mechanisms. The canonical pairing is with Selank, and this combination has been studied enough that some Russian clinical work treats them as a coordinated intervention.

• Selank — orthogonal mechanism (GABAergic/anxiolytic vs. neurotrophic/cognitive). Researchers typically separate the two in time to isolate endpoints, but the pairing is well-represented in Russian protocol literature. See the Selank entry.
• BPC-157 — mechanistically unrelated; used in protocols targeting both CNS and somatic repair. See the BPC-157 entry.
• Other melanocortin-acting peptides (e.g., PT-141) — overlap at the receptor family level. Concurrent administration is not characterized in the literature and is typically avoided in structured protocols. See the PT-141 entry.